NCT04371965 (KILLER) is a Phase 2 clinical trial of Povidone-Iodine in COVID-19, sponsored by Poitiers University Hospital.

Who is sponsoring NCT04371965?

NCT04371965 is sponsored by Poitiers University Hospital.

What drugs are being tested in NCT04371965?

Interventions in NCT04371965: Povidone-Iodine.

Is NCT04371965 still recruiting?

NCT04371965 is currently completed. Last updated 26 October 2020.

Last reviewed 2020-10-26 · How we verify

NCT04371965: KILLER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19

Completed Phase 2 Last updated 26 October 2020

What this trial tests

Phase 2 trial testing Povidone-Iodine in COVID-19 in 24 participants. Completed in 23 October 2020.

Timeline

1 September 2020

Primary endpoint
23 October 2020

23 October 2020

Quick facts

Lead sponsor	Poitiers University Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	1 September 2020
Primary completion	23 October 2020
Estimated completion	23 October 2020
Sites	1 location across France

Drugs / interventions tested

Povidone-Iodine — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Poitiers University Hospital

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The SARS-CoV-2 coronavirus pandemic is responsible for more than 180,000 deaths worldwide and 20,000 deaths in France. To date, no treatment or vaccine has been successful. Povidone-iodine is an antiseptic suitable for use on the skin and mucosa with potent virucidal activity, particularly against coronaviruses. It is marketed for oro-nasopharyngeal decolonization. 24 patients with positive nasopharyngeal SARS-CoV-2 carriage will be randomized (1:1) in an experimental group (benefiting from povidone iodine decolonization) or a control group. Patients in the experimental group will be asked to gargle with a 1% povidone-iodine solution, spray their nose with the same antiseptic solution, and finally applied 10% povidone-iodine cream in each nostril, all four times a day for five days. Patients will be followed for 7 days to evaluate the efficacy and safety of povidone iodine decolonization.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Pharmaceutical assessment of polyvinylpyrrolidone (PVP): As excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition.
Kurakula M, Rao GSNK. · · 2020 · cited 207× · PMID 32905026 · DOI 10.1016/j.jddst.2020.102046
Role of vitamins and minerals as immunity boosters in COVID-19.
Kumar P, Kumar M, Bedi O, Gupta M, et al · · 2021 · cited 75× · PMID 34110533 · DOI 10.1007/s10787-021-00826-7
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895
Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19: A Randomized Clinical Trial.
Guenezan J, Garcia M, Strasters D, Jousselin C, et al · · 2021 · cited 62× · PMID 33538761 · DOI 10.1001/jamaoto.2020.5490
Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them.
Burton MJ, Clarkson JE, Goulao B, Glenny AM, et al · · 2020 · cited 39× · PMID 32936948 · DOI 10.1002/14651858.cd013627.pub2
Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection.
Burton MJ, Clarkson JE, Goulao B, Glenny AM, et al · · 2020 · cited 25× · PMID 32936949 · DOI 10.1002/14651858.cd013626.pub2
Review of the use of nasal and oral antiseptics during a global pandemic.
Stathis C, Victoria N, Loomis K, Nguyen SA, et al · · 2021 · cited 21× · PMID 33464122 · DOI 10.2217/fmb-2020-0286
Antimicrobial mouthwashes (gargling) and nasal sprays to protect healthcare workers when undertaking aerosol-generating procedures (AGPs) on patients without suspected or confirmed COVID-19 infection.
Burton MJ, Clarkson JE, Goulao B, Glenny AM, et al · · 2020 · cited 16× · PMID 32936947 · DOI 10.1002/14651858.cd013628.pub2

Verify or expand the search:

Other trials of Povidone-Iodine

Trials testing the same drug.

NCT07044726 — Betadine vs Sterile Water for Periurethral Preparation · Phase 4 · not yet recruiting
NCT07460297 — Pseudomonas Aeruginosa Injection Combined With Polyvinylpyrrolidone-Iodine in Immediate Breast Reconstruction Surgery Wi · NA · enrolling by invitation
NCT06667089 — Povidone-Iodine Versus Chlorhexidine in Surgical Wound Care · NA · completed
NCT05919888 — SURGX Antimicrobial Gel Versus Povidone-iodine Skin Incision Prep in Total Shoulder Arthroplasty · Phase 4 · completed
NCT05895773 — Oro-nasal Decontamination to Prevent Ventilator-associated Pneumonia · Phase 2, PHASE3 · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Poitiers University Hospital trials

Trials by the same sponsor.

NCT07350291 — Evaluation of the Diagnostic Capabilities of Saliva Samples From Pediatric Patients, Promoting Active Involvement of the · NA · not yet recruiting
NCT07411651 — Confirmation of the Link Between Endocrine Disruptors Exposure and Breast Cancer and Identification of Biological Respon · NA · not yet recruiting
NCT07463963 — Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post-operative Febr · NA · not yet recruiting
NCT07475442 — Prognostic Factors of Hospitalization for Patients Aged 75 and Over in Emergency Department in France - Monocentric Retr · not yet recruiting
NCT07412717 — The Efficacy of Combining Music Intervention With Nicotine Replacement Therapy to Reduce Smoking Craving, Among Healthca · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04371965 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Poitiers University Hospital
Last refreshed: 26 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04371965.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing